About The Study: The results of this cohort study suggest that combining plasma p-tau217 and Aβ42/40 levels could be useful for predicting development of Aβ pathology in people with early stages of subthreshold Aβ accumulation. These biomarkers might thus facilitate screening of participants for future primary prevention trials.
About The Study: The results of this cohort study suggest that combining plasma p-tau217 and Aβ42/40 levels could be useful for predicting development of Aβ pathology in people with early stages of subthreshold Aβ accumulation. These biomarkers might thus facilitate screening of participants for future primary prevention trials.
Corresponding Authors: To contact the corresponding authors, email Oskar Hansson, M.D, Ph.D. (Oskar.Hansson@med.lu.se) and Shorena Janelidze, Ph.D. (shorena.janelidze@med.lu.se).
To access the embargoed study: Visit our For The Media website at this link
(doi:10.1001/jamaneurol.2024.2619)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the Alzheimer’s Association International Conference.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
Journal
JAMA Neurology
Discover more from Science
Subscribe to get the latest posts sent to your email.
